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Long QT Syndrome
Risk of Fatal Arrhythmic Events in
Long QT Syndrome Patients After Syncope
Christian Jons, MD,* Arthur J. Moss, MD,* Ilan Goldenberg, MD,* Judy Liu, MS,* Scott McNitt, MS,*
Wojciech Zareba, MD, PHD,* Ming Qi, MD,† Jennifer L. Robinson, MS*
Rochester, New York
Objectives The aim of this study was to identify risk factors for fatal arrhythmias in long QT syndrome (LQTS) patients pre-
senting with syncope.
Background Syncope is highly predictive for future fatal arrhythmias in the LQTS. However, there are no data regarding risk
stratification and management strategies in the high-risk subset of LQTS patients presenting with syncope.
Methods A total of 1,059 LQTS patients with a corrected QT interval 450 ms presenting with syncope as a first symp-
tom were drawn from the International LQTS Registry. Cox proportional hazards regression was used to identify
risk factors for a severe arrhythmic events comprising aborted cardiac arrest, appropriate implantable
cardioverter-defibrillator therapy, and sudden cardiac death.
Results The lowest risk was found in patients with only 1 syncopal episode occurring before the start of beta-blocker
therapy. In contrast, patients experiencing syncope after starting beta-blocker therapy had a 3.6-fold increase in
the risk of severe arrhythmic events (p  0.001) relative to this low-risk group and displayed a risk of severe
arrhythmic events similar to that of patients not treated with beta-blockers. Multiple syncopal episodes occurring
before initiation of beta-blocker therapy were associated with an intermediate risk (hazard ratio: 1.8,
p  0.001). The risk of syncope during beta-blocker therapy is high during childhood in both sexes but is
higher in women than in men (hazard ratio: 2.3, p  0.001).
Conclusions Patients with syncope during beta-blocker therapy are at high risk of life-threatening events, and implantable
cardioverter-defibrillator therapy should be considered in these patients. The risk of beta-blocker failure is high-
est in young children and in women. (J Am Coll Cardiol 2010;55:783–8) © 2010 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.042s
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Song QT syndrome (LQTS) is caused by mutations in genes
ncoding cardiac potassium and sodium ion channel subunits
r cellular structural proteins. Patients often present with
ymptoms at a young age and are at high risk of nonfatal
syncope) and fatal (sudden cardiac death [SCD]) cardiac
vents (1). The incidence of syncope in LQTS patients is
pproximately 5% per year (1), depending on the mutation
ausing the syndrome (2,3), whereas the incidence of SCD is
uch lower, approximately 1.9% per year (1). However,
onfatal events remain the strongest predictor of fatal events in
QTS patients (1,4), and the overall risk of subsequent SCD
n an LQTS patient who has experienced a previous episode of
yncope is approximately 5% per year (1). Thus, an LQTS
atient who presents for clinical assessment after a nonfatal
rom the Cardiology Division of the Departments of *Medicine, and †Pathology,
niversity of Rochester Medical Center, Rochester, New York. Dr. Moss has received
research grant from Bioreference Labs. Dr. Liu has received a fellowship funded by
he Clinical and Translational Science Institute, and a grant from the NIH.t
Manuscript received August 13, 2009, revised manuscript received November 23,
009, accepted November 30, 2009.yncopal episode is already at high risk of a subsequent
QTS-related fatal event. Recent studies from the Interna-
ional LQTS Registry identified risk factors for cardiac events
n LQTS patients (1,3,5–9). However, there are no data
egarding specific risk factors for SCD within the high-risk
ubgroup of symptomatic LQTS patients who have experi-
nced a previous syncopal episode. Thus, the subsequent
reatment of these patients depends largely on the clinical
udgment of the physician based on risk assessment. Specifi-
ally, a paucity of data exists regarding the management of
QTS patients who experience syncope while on beta-blocker
herapy. The aim of this study was to determine clinical
redictors of subsequent SCD in LQTS patients presenting to
he clinician with first syncopal episode and to evaluate the
fficacy of beta-blocker therapy for the prevention of sudden
eath in this high-risk population.
ethods
tudy population. The study population was drawn from
he International LQTS Registry (10) and included affected or
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Risk Stratification After the First Syncope Event in LQTS February 23, 2010:783–8genotype-positive individuals born
after 1959 to maximize the num-
ber of patients who were treated
with beta-blockers. Patients were
followed through age 41 years. Af-
fected individuals were defined as
any subject with a corrected QT
(QTc) interval of 450 ms, as
corrected by Bazett’s formula (11),
who experienced a syncopal epi-
sode. The final study group com-
prised 1,059 LQTS subjects from
764 families. The LQTS genotype
was determined with standard
mutational analytic techniques in-
olving 5 established genetic laboratories associated with the
nternational LQTS Registry. Genotype data were available
or 445 patients (LQT1  212, LQT2  163, LQT3  35,
QT5  4, LQT6  3, LQT7  2, LQT8  1; genotype-
egative affected  36). Symptomatic genotype-negative sub-
ects according to the above criteria were included if incomplete
enetic studies had been performed.
eta-blocker therapy. Beta-blocker therapy was initiated at
he discretion of each patient’s attending physician. During the
nitial patient contact, information was collected on whether
eta-blocker treatment had been started, the specific beta-
locker initiated, the date started, the prescribed dose, and the
atient’s weight. At subsequent yearly contacts, information
as recorded on whether the patient continued taking beta-
lockers and, if so, the daily dose; if patients discontinued
herapy, the date that the medication was stopped was re-
orded. Among patients who died, we retrospectively deter-
ined whether the patient had been taking a prescribed
eta-blocker before and on the day of death.
yncopal events. Episodes of loss of consciousness were
ategorized as syncope if the episode was abrupt in onset and
ffset. Patients were classified into 3 prespecified categories
ased on the clinical nature of the syncopal events: 1) a first
yncopal event in patients not receiving beta-blocker therapy;
) repeated syncopal events in patients not receiving beta-
locker therapy; and 3) any syncopal event occurring in
atients receiving beta-blocker therapy. Patients in the last
ategory could have had any number of syncopal episodes while
ff beta-blocker therapy before the final episode while on
eta-blocker therapy. Once a patient experienced a syncopal
vent while receiving beta-blocker therapy, the patient re-
ained in this group independently of future syncopal events
nd treatment.
nd points. The primary end point was a life-threatening
ardiac event. Twenty percent (n  212) of the study popula-
ion had an implantable cardioverter-defibrillator (ICD) im-
lanted. We therefore used the end point of severe arrhythmic
vents (SAEs) defined as LQTS-related SCD, aborted cardiac
rrest, or appropriate ICD therapy for an LQTS-related
entricular tachyarrhythmia, whichever occurred first. Adjudi-
Abbreviations
and Acronyms
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LCTS  left cervicothoracic
sympathectomy
LQTS  long QT syndrome
QTc  corrected QT
SAE  severe arrhythmic
event
SCD  sudden cardiac
deathation of the ICD treatment as appropriate or inappropriate sas performed by the treating electrophysiologist at the time of
CD interrogation.
tatistical analysis. Variables were tested for normality using
isual inspection. Student t test and Pearson’s chi-square test
ere used in the univariate comparison analyses where appro-
riate. The cumulative probability of a first cardiac event was
ssessed by the Kaplan-Meier method with significance testing
y the log-rank statistic. The Cox proportional hazards survi-
orship model was used to evaluate the independent contribu-
ion of clinical and genetic factors to the first occurrence of
ime-dependent cardiac events from birth through age 40
ears. Pre-specified covariates included in the multivariate
odel were QTc duration, sex, history of syncope, and
ime-dependent beta-blocker therapy. Beta-blocker treatment,
yncope, and the interaction between recurrent syncope and
eta-blocker therapy were treated as time-dependent covariates
n a Cox model, and all reported hazard ratios (HRs) and p
alues stem from these models.
To illustrate the risk associated with syncopal events occur-
ing while on and off beta-blocker therapy, Kaplan-Meier
urvival curves for patients, all experiencing 1 syncopal event
hile off beta-blocker therapy, were created for the following
reatment and syncopal groups: 1) patients not starting beta-
locker treatment after first syncope; 2) patients starting
eta-blocker treatment after the first syncopal event and
xperiencing no subsequent syncope during beta-blocker treat-
ent; and 3) patients starting beta-blocker treatment after
he first episode of syncope and experiencing subsequent
yncope episodes during beta-blocker treatment. All patients
ere initially in group 1, and the time of the syncope occurring
hile off beta-blocker therapy was used as time origin. If
atients started beta-blocker therapy, they moved into group 2,
ow using time of initiation of beta-blocker treatment as the
ime origin for outcome. If patients in group 2 experienced
yncope during beta-blocker treatment, they moved into group
, now with the time of the syncope occurring while receiving
eta-blocker treatment as the time origin.
Similarly, the figure showing the risk of syncope occur-
ing during beta-blocker treatment was constructed with
atients in the corresponding age and sex groups at the time
f beta-blocker treatment initiation. If the patients started
eta-blocker treatment before age 14 years and were fol-
owed past age 14 years, the patient was censored at age 14
ears and restarted at time 0 in the appropriate sex group
ith the 14th birthday as the origin of the curve. The
ethodology shown in Figures 1 and 2 was used for
llustrative purposes only, and no hypothesis testing was
one using this approach.
All statistical analyses were performed using SAS version
.1.3 (SAS Institute, Cary, North Carolina).
esults
tudy population. Baseline characteristics of the study
opulation by the occurrence of SAEs during follow-up are
hown in Table 1. The group with SAEs had a lower
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herapy at a younger age than those without SAEs. A larger
roportion of patients with SAEs was treated with device
herapy or surgery, indicating the severe clinical presenta-
ion of the syndrome in this group. The type and dose of
eta-blocker treatment were balanced in the 2 groups.
Figure 1 The Cumulative Risk of Severe Arrhythmic Events and
The solid black line represents all patients after the first syncopal event until star
resented by the red dashed line. Patients with a syncopal event occurring while of
section for how this graph was constructed.
Figure 2 Risk of the First Syncope Event on Beta-Blocker Trea
From the Start of Beta-Blocker Treatment or From the
Patients were followed from the time that beta-blocker therapy was started in theisk factor for SAEs. A total of 210 SAEs occurred, of
hich 82 (39%) occurred during beta-blocker treatment.
here were no differences in the proportion of the SAEs
hat occurred during beta-blocker treatment among patients
ith LQT1 (45%), LQT2 (33%), and LQT3 (40%) (p 
.48).
-Blocker Therapy
ta-blocker (BB) therapy. After the start of beta-blocker therapy, patients are rep-
blocker therapy are represented by the purple dashed line. See the Methods
t
h Birthday
tive sex groups. See the Methods section for how this graph was constructed.Beta
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f beta-tmen
14t
respec
s
T
b
a
S
d
S
A
o
p
0
s
t
p
a
e
s
a
a
e
f
w
0
s
p
m
t
d
p
a
a
i
i
t
R
b
w
b
c
f
t
b
t
t
s
p
p
p
t
e
(
0
1
D
T
w
CSa
*
CT
V
1
p
L
c
786 Jons et al. JACC Vol. 55, No. 8, 2010
Risk Stratification After the First Syncope Event in LQTS February 23, 2010:783–8The most important risk factor for SAEs was whether a
yncopal episode occurred during beta-blocker treatment.
his is illustrated in Figure 1. Patients who began beta-
locker therapy after their first and only syncopal episode
nd did not experience further episodes were at low risk of
AEs. However, patients experiencing syncopal episodes
uring beta-blocker therapy were at the same high risk of
AEs as patients who never started beta-blocker therapy.
ccordingly, in a multivariate analysis (Table 2), syncope
ccurring during beta-blocker treatment was the most
owerful predictor of subsequent SAEs (HR: 3.6, p 
.001). Patients who experienced multiple versus single
yncopal episodes while off beta-blocker treatment had
wice the risk of an SAE. Beta-blockers were generally
rotective against SAEs, and there were no significant sex or
ge group interactions. The risk of SAEs after a syncopal
vent was also significantly increased among patients with
evere QTc interval prolongation (QTc interval 500 ms)
nd female patients in the 14 to 40 years age group. Females
nd males have a similar risk of SAEs after the first syncopal
linical Characteristics andreatment in the Study PopulationTable 1 Clinical Characteristics andTreatment in the Study Population
No Severe
Arrhythmic
Events
Severe
Arrhythmic
Events
Clinical variables
n 849 210
Male 536 (63) 143 (68)
Deafness 28 (3) 17 (8)*
Proband 440 (61) 217 (66)
Age at first syncope, yrs 12.3 7.8 11.4 7.8
Genotyped subjects (n 409)
LQT1 181 (21) 31 (15)
LQT2 127 (15) 36 (17)
LQT3 30 (4) 5 (2)
Other genotype 8 (1) 2 (1)
Multiple mutations† 11 (3) 5 (7)
Electrocardiogram
QTc interval at baseline (ms) 502 5 510 6
Number of subjects with QTc interval 500 ms 290 (34) 107 (51)*
Treatment during the study
Beta-blocker therapy started (n 830) 722 (85) 108 (51)*
Age at initiation of beta-blocker therapy, yrs 15.5 9.3 12.9 8.4*
Propranolol (n 433) 372 (52) 64 (59)
Nadolol (n 89) 87 (12) 7 (7)
Metoprolol (n 92) 82 (11) 10 (9)
Atenolol (n 179) 166 (23) 22 (20)
Other beta-blocker (n 20) 15 (2) 5 (5)
Received beta-blocker therapy during SAE — 82 (39)
Pacemaker implanted 106 (13) 20 (16)
ICD implanted 177 (21) 35 (17)
LCTS surgery 41 (5) 11 (5)
alues are n (%) or mean  SD. *Significant differences between the 2 groups with p  0.05. †Of
6 patients with compound mutations, 4 patients had mutations in the same gene, whereas 12
atients had mutations in multiple genes (LQT1  LQT2  4, LQT1  LQT2  4, LQT1  LQT5  1,
QT2  LQT3  2, LQT1  SNTA1  1).
ICD implantable cardioverter-defibrillator; LCTS left cervicothoracic sympathectomy; QTc
orrected QT; SAE  severe arrhythmic event.pisode during the preteen years, but after age 14 years,
†emale patients had almost twice the risk of SAEs compared
ith male patients in the same age group (HR: 1.86, p 
.001).
Fifty-two patients were treated with left cervicothoracic
ympathectomy (LCTS) during the course of the study. All
atients started beta-blocker therapy before LCTS, and
ost patients (43 [83%]) remained on beta-blocker therapy
hroughout the study. Six SAEs occurred in this group
espite concomitant treatment with beta-blockers. The
atients receiving LCTS had longer QTc intervals, both
mong subjects with SAEs (QTc interval  519  5 ms)
nd without SAEs (QTc interval  520  5 ms), but were
n other aspects similar to the study population. The few
ndividuals with sympathectomy did not allow evaluation of
his treatment in the Cox models.
isk factors for recurrent syncope during treatment with
eta-blockers. To determine the risk for recurrent syncope
hile receiving beta-blocker therapy, 746 patients in whom
eta-blocker therapy was initiated after experiencing syn-
ope were included in a subset analysis. In this analysis,
ollow-up time was assessed from the date beta-blocker
herapy was initiated.
As illustrated in Figure 2, the risk of syncope during
eta-blocker treatment did not show any association with
he QTc interval, but the risk was markedly influenced by
he age and sex of the patients. Figure 2 shows a high but
imilar risk of syncope during beta-blocker treatment before
uberty in both sexes. However, after puberty, female
atients remain at high risk, whereas the risk in male
atients decreases markedly. Table 3 shows the results from
he multivariate analysis. There were no significant differ-
nces between male and female patients ages 0 to 13 years
HR: 1.04, p 0.85) as well as between female patients ages
to 13 years and female patients ages 14 to 40 years (HR:
.39, p  0.10).
iscussion
his study highlights the association of syncopal episodes
ith the subsequent risk of potentially fatal arrhythmic
ox Model for Risk Factors Related to Severeardiac Events in Patients Pr senting With the Firstyncope Event a d Repeated Syncope Even s Onnd Off B ta-Blocker Th rapy
Table 2
Cox Model for Risk Factors Related to Severe
Cardiac Events in Patients Presenting With the
First Syncope Event and Repeated Syncope Events
On and Off Beta-Blocker Therapy
Parameter HR 95% Cl p Value
Syncopal episodes and beta-blocker therapy
1 syncopal events on beta-blocker
therapy*
3.59 2.25–5.74 0.001
1 syncopal event off beta-blocker
therapy*
1.96 1.37–2.82 0.001
QTc interval 500 ms 1.76 1.32–2.27 0.001
Female subjects age 14 to 40 yrs† 1.86 1.40–2.49 0.001
Time-dependent beta-blocker therapy 0.46 0.32–0.65 0.001
Relative to subjects with only 1 syncopal episode occurring while off beta-blocker therapy.
Relative to male subjects age 14 to 40 years.
CI  confidence interval; HR  hazard ratio; QTc  corrected QT.
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February 23, 2010:783–8 Risk Stratification After the First Syncope Event in LQTSvents in LQTS patients. New important findings in this
tudy are as follows: 1) in LQTS patients presenting with
he first syncopal episode, fatal arrhythmic events are effec-
ively prevented with beta-blocker treatment in those with-
ut recurrent syncope; 2) patients experiencing syncope
hile receiving beta-blocker therapy are at high risk of
ubsequent SAEs, a risk similar to that observed in patients
ho are not treated with beta-blockers; and 3) there is an
mportant sex difference in the risk of experiencing syncope
hile being treated with beta-blockers. Before puberty, the
fficacy of beta-blockers in preventing subsequent syncopal
pisodes seems to be equal in both sexes, whereas after age
4 years, this risk is drastically lowered in male patients, but
ot among female patients. The risk of syncope while being
reated with beta-blockers among patients with previous
yncopal events does not seem to be related to the QTc
nterval.
yncope, beta-blocker treatment, and prevention of cardiac
eath in LQTS patients. Why some patients keep having
ymptoms despite treatment with beta-blockers is unknown.
possible explanation may be the known patient variability
n beta-blocker efficacy in blocking sympathetic activation
12,13) that may have genetic underpinnings. In a previous
tudy, failure of beta-blocker therapy was related to the
enotype, because LQT1 genotype-positive subjects
howed the highest proportion of beta-blocker therapy
ailures, and to the type of beta-blocker used (14). This
nding contrasts with our study in which the type of
eta-blocker did not significantly influence the results,
nd beta-blocker effects were consistent across genotypes.
nstead we found that sex and age had an influence on the
isk of syncope while receiving beta-blocker treatment.
hose experiencing syncope on beta-blocker therapy
ere at high risk of SAEs.
A recent study evaluated occurrences of aborted cardiac
rrest/SCD in LQTS subjects receiving beta-blocker ther-
py and found that a significant number of these events were
ue to noncompliance or concomitant treatment with QT-
rolonging drugs (15). We were not able to investigate this,
ut noncompliance is an important confounder in this
isk Factors for the First Syncope Eventfter the Start of Beta-Blocker Tr atment inong QT Syndr me Patients With Previouspisodes f Syncop
Table 3
Risk Factors for the First Syncope Event
After the Start of Beta-Blocker Treatment in
Long QT Syndrome Patients With Previous
Episodes of Syncope
Parameter HR 95% Cl p Value
Male subjects age 0 to 13 yrs vs.
male subjects age 14 to 40 yrs
3.16 1.92–5.78 0.001
Female subjects age 0 to 13 yrs vs.
male subjects age 14 to 40 yrs
3.04 1.82–5.08 0.001
Female subjects age 14 to 40 yrs vs.
male subjects age 14 to 40 yrs
2.27 1.45–3.58 0.001
QTc interval 500 ms 1.10 0.86–1.42 0.46
bbreviations as in Table 2.opulation consisting of mainly young individuals prone to fide effects. However, we cannot explain why noncompli-
nce should be much higher in female patients older than 14
ears than in male patients older than 14 years, and we
elieve that other factors such as sex hormones are likely to
lay a role in this difference.
CD treatment in LQTS patients presenting with a
yncope. When to treat a symptomatic LQTS patient with
n ICD is an important clinical question, and the benefits
nd risk of ICD therapy in high-risk LQTS patients have
et to be defined. The risk of SAEs in LQTS patients
resenting with syncope is low if treated with beta-blockers.
owever, experiencing syncope while being treated with
eta-blocking agents is a high-risk situation, and this study
hows that the risk of fatal arrhythmias in such patients can
e considered equal to the risk in patients not treated with
eta-blockers. Even though some of the syncope episodes in
his study could have occurred because of noncompliance or
ndertreatment, it is unlikely that these nontherapy factors
xplain our findings. ICD therapy is very effective in
reventing SCD in LQTS patients (16–18), and ICD
herapy should be considered in patients experiencing syn-
ope during beta-blocker treatment.
tudy limitations. Beta-blocker treatment was not allo-
ated at random, and unmeasured factors could have influ-
nced the effects of therapy. Also, the efficacy of beta-
lockers has been linked to the genotype of the patients.
nly a subset of the study subjects in this study was
enotyped, and the small number of end points in these
atients did not allow us to address differences between the
ifferent genotypes. We did separate models for LQT1 and
QT2 patients and found identical patterns for the beta-
locker treatment. We believe that the bias caused by
nknown phenotype is small and that the reported results
re applicable to most genotypes. Family membership of the
tudy subjects is likely to be influenced by other genotypic
raits in the family. In this study, only a few study subjects
ere related, and we did not find any difference in the
esults when using the covariance estimator sandwich (19)
o adjust for family membership. The impact of LCTS
urgery on the study results could not be fully evaluated due
o limited power in the Cox analysis.
onclusions
n general, LQTS patients presenting with syncope are
ffectively treated with beta-blockers. However, patients
xperiencing 1 syncopal events during beta-blocker ther-
py are at the same risk of fatal events as patients who were
ot treated with beta-blockers. Thus, ICD treatment should
e considered in these high-risk patients. The risk of
yncopal events during beta-blocker treatment is highest
efore puberty. After puberty, the risk remains high in
emale patients.
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APPENDIX
or a list of the investigators from the International Long QT Syndrome
egistry who contributed patients to the study, please see the online
ersion of this article.
